Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive breast …

Mar 3, 2025 · Trastuzumab deruxtecan is FDA-approved for the treatment of HER2-positive metastatic breast cancers that have progressed on at least one past HER2-targeted therapy for metastatic …

Dec 2, 2025 · Targeted therapy is a treatment for certain types of breast cancer. Learn about types of targeted therapy, common side effects, and more.

21 hours ago · For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer — Resistance to initial therapy sets the stage for many other options

Jun 17, 2025 · The current treatment landscape for HER2-positive metastatic breast cancer has evolved significantly, with recent updates further refining patient care strategies. Historically, the …

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.

1 day ago · As such, there is an unmet need for developing more effective first-line maintenance treatments in HER2-positive metastatic breast cancer.

Oct 13, 2024 · Herceptin was the first ever targeted therapy for HER2-positive breast cancer and has been approved for over twenty years. It’s safe and effective and extends the life of MBC patients. …

2 days ago · The trial enrolled 654 patients with HER2-positive advanced breast cancer who had completed four to eight cycles of induction chemotherapy plus trastuzumab and pertuzumab, without …